Cost Analysis of Adverse Events Associated with First Line Treatment for Metastatic Renal Cell Carcinoma (MRCC) in the Perspective of Public and Private Health Insurance in Brazil
Abstract
Authors
C.N. Ferreira C.S. Rufino D.F. Manfrin